ADMS Stock UPDATES Adamas Pharmaceuticals Inc. (ADMS) 14.33 10/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adamas Pharmaceuticals Inc. (ADMS) 14.33 $ADMS

OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 14.33 (+0.01)

5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 96.97 (+1.99), RCAP: 19.97 (+1.12), ADMS: 14.33 (+0.01), TRGP: 128.50 (+2.53), NRG: 28.61 (+0.17)

Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 14.33 (+0.01)

Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 14.33 (+0.01), FRX: 99.00 (-0.77)

Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 14.33 (+0.01)

United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 14.33 (+0.01)

Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
MNK: 89.30 (+2.15), AKRX: 41.29 (+2.28), ADMS: 14.33 (+0.01), RDY: 49.61 (+0.77)

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
ACT: 232.13 (+5.46), GILD: 106.67 (+4.46), ADMS: 14.33 (+0.01), FRX: 99.00 (-0.77)

Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
PR Newswire - Mon Jun 16, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time.
ADMS: 14.33 (+0.01)

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
ACT: 232.13 (+5.46), ADMS: 14.33 (+0.01), ANIP: 28.09 (+0.30), FRX: 99.00 (-0.77)

Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.
ADMS: 14.33 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading